Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097435 · ClinicalTrials.gov registry record · Phase 2
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 8
- Study locations
NCT00097435: Completed Phase 2 study of Hepatitis C, sponsored by Human Genome Sciences.
NCT00097435 is a Phase 2 study of Hepatitis C that has completed, run by Human Genome Sciences. The registered enrollment target is 115 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00097435, a Phase 2 study of Hepatitis C, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
Conditions Studied
Interventions
- DRUG Albuferon
- DRUG Ribavirin
Study Locations (8)
Florida
- University of Florida CRC - Gainesville
- University of Florida at Jacksonville - Jacksonville
- Mayo Clinic Jacksonville - Jacksonville
Arizona
- Mayo Clinic - Phoenix
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic Rochester - Rochester
North Carolina
- Duke University - Durham
Virginia
- Metropolitan Research - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00097435 record still lists
NCT00097435 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Albuferon is the first listed.
NCT00097435 lists 8 locations in 6 states (Florida, Arizona, Maryland).
Frequently Asked Questions
What is clinical trial NCT00097435 about?
NCT00097435 is a clinical study titled "A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C". This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
What is the current status of trial NCT00097435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2004-10. Estimated completion is 2007-08.
What conditions does trial NCT00097435 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00097435?
The interventions under investigation include: Albuferon (DRUG), Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00097435?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00097435 being conducted?
This trial has 8 study locations across Arizona, Florida, Maryland, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00097435's enrollment target sits among peer trials
115 53rd of 106 higher than 53 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
-
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia